Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

In a large, multinational, randomized trial, continuous lenalidomide maintenance therapy after triplet therapy (lenalidomide, bortezomib, and dexamethasone) and autologous stem-cell transplantation resulted in longer progression-free survival than triplet therapy alone.

Saved in:
Bibliographic Details
Published in:The New England journal of medicine Vol. 387; no. 2; pp. 132 - 147
Main Authors: Richardson, Paul G., Jacobus, Susanna J., Weller, Edie A., Hassoun, Hani, Lonial, Sagar, Raje, Noopur S., Medvedova, Eva, McCarthy, Philip L., Libby, Edward N., Voorhees, Peter M., Orlowski, Robert Z., Anderson, Larry D., Zonder, Jeffrey A., Milner, Carter P., Gasparetto, Cristina, Agha, Mounzer E., Khan, Abdullah M., Hurd, David D., Gowin, Krisstina, Kamble, Rammurti T., Jagannath, Sundar, Nathwani, Nitya, Alsina, Melissa, Cornell, R. Frank, Hashmi, Hamza, Campagnaro, Erica L., Andreescu, Astrid C., Gentile, Teresa, Liedtke, Michaela, Godby, Kelly N., Cohen, Adam D., Openshaw, Thomas H., Pasquini, Marcelo C., Giralt, Sergio A., Kaufman, Jonathan L., Yee, Andrew J., Scott, Emma, Torka, Pallawi, Foley, Amy, Fulciniti, Mariateresa, Hebert, Kyle, Samur, Mehmet K., Masone, Kelly, Maglio, Michelle E., Zeytoonjian, Andrea A., Nadeem, Omar, Schlossman, Robert L., Laubach, Jacob P., Paba-Prada, Claudia, Ghobrial, Irene M., Perrot, Aurore, Moreau, Philippe, Avet-Loiseau, Hervé, Attal, Michel, Anderson, Kenneth C., Munshi, Nikhil C.
Format: Journal Article
Language:English
Published: United States Massachusetts Medical Society 14.07.2022
Subjects:
Adult
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - adverse effects
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Autografts
Bone marrow
Bone Marrow Transplantation
Bortezomib
Bortezomib - administration & dosage
Bortezomib - adverse effects
Cancer
Confidence intervals
Dexamethasone
Dexamethasone - administration & dosage
Dexamethasone - adverse effects
Disease Progression
Disease-Free Survival
Hematology
Humans
Immunotherapy
Inhibitor drugs
Lenalidomide - administration & dosage
Lenalidomide - adverse effects
Leukemia
Lymphoma
Maintenance Chemotherapy - methods
Medical prognosis
Melphalan
Melphalan - administration & dosage
Multiple myeloma
Multiple Myeloma - diagnosis
Multiple Myeloma - drug therapy
Multiple Myeloma - surgery
Oncology
Patients
Quality of life
Stem Cell Transplantation
Targeted cancer therapy
Transplantation, Autologous
Treatments in Oncology
ISSN:0028-4793, 1533-4406, 1533-4406
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In a large, multinational, randomized trial, continuous lenalidomide maintenance therapy after triplet therapy (lenalidomide, bortezomib, and dexamethasone) and autologous stem-cell transplantation resulted in longer progression-free survival than triplet therapy alone.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2204925